AbbVie's Dual-Targeting Therapy Shows Higher Remission Rates In Mid-Stage Crohn's Disease Study

AbbVie reported positive Phase 2a results for investigational therapy ABBV-466 in moderate to severe Crohn’s disease. The treatment achieved higher rates of endoscopic remission than either component therapy alone; the provided article text contains no numerical remission rates or further trial details.